CN102552159A - 雷贝拉唑钠肠溶微丸及其制备方法 - Google Patents
雷贝拉唑钠肠溶微丸及其制备方法 Download PDFInfo
- Publication number
- CN102552159A CN102552159A CN2010106031819A CN201010603181A CN102552159A CN 102552159 A CN102552159 A CN 102552159A CN 2010106031819 A CN2010106031819 A CN 2010106031819A CN 201010603181 A CN201010603181 A CN 201010603181A CN 102552159 A CN102552159 A CN 102552159A
- Authority
- CN
- China
- Prior art keywords
- enteric
- sodium
- rabeprazole
- layer
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- ZGDLVKWIZHHWIR-UHFFFAOYSA-N 4-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]morpholine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(N2CCOCC2)N=C1 ZGDLVKWIZHHWIR-UHFFFAOYSA-N 0.000 title claims abstract description 25
- 229960001778 rabeprazole sodium Drugs 0.000 title claims abstract description 25
- 239000008188 pellet Substances 0.000 title abstract description 13
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims abstract description 34
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 25
- 239000004408 titanium dioxide Substances 0.000 claims abstract description 17
- 239000000463 material Substances 0.000 claims abstract description 12
- 239000003381 stabilizer Substances 0.000 claims abstract description 12
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 10
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 10
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 9
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000000395 magnesium oxide Substances 0.000 claims abstract description 7
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims abstract description 7
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims abstract description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims abstract description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims abstract description 6
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims abstract description 3
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000000292 calcium oxide Substances 0.000 claims abstract description 3
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 claims abstract description 3
- 235000012255 calcium oxide Nutrition 0.000 claims abstract description 3
- 235000012245 magnesium oxide Nutrition 0.000 claims abstract description 3
- 239000011736 potassium bicarbonate Substances 0.000 claims abstract description 3
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims abstract description 3
- 235000015497 potassium bicarbonate Nutrition 0.000 claims abstract description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims abstract description 3
- 235000011181 potassium carbonates Nutrition 0.000 claims abstract description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims abstract description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims abstract description 3
- 235000017550 sodium carbonate Nutrition 0.000 claims abstract description 3
- 229960004157 rabeprazole Drugs 0.000 claims description 34
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 claims description 34
- 238000007789 sealing Methods 0.000 claims description 20
- 239000010410 layer Substances 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 17
- 239000011248 coating agent Substances 0.000 claims description 15
- 238000000576 coating method Methods 0.000 claims description 15
- 239000012055 enteric layer Substances 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 239000004014 plasticizer Substances 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 239000004925 Acrylic resin Substances 0.000 claims description 7
- 239000006187 pill Substances 0.000 claims description 6
- 229920000178 Acrylic resin Polymers 0.000 claims description 5
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 claims description 4
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 239000002702 enteric coating Substances 0.000 claims description 3
- 238000009505 enteric coating Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 230000008961 swelling Effects 0.000 claims description 3
- 239000001069 triethyl citrate Substances 0.000 claims description 3
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 3
- 235000013769 triethyl citrate Nutrition 0.000 claims description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 229960003511 macrogol Drugs 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 2
- 150000005690 diesters Chemical class 0.000 claims 1
- 229940075507 glyceryl monostearate Drugs 0.000 claims 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims 1
- -1 sealing coat Substances 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 6
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 229920001531 copovidone Polymers 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 239000002775 capsule Substances 0.000 description 11
- 239000002253 acid Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940126409 proton pump inhibitor Drugs 0.000 description 4
- 239000000612 proton pump inhibitor Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000008118 PEG 6000 Substances 0.000 description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 239000005030 aluminium foil Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000003605 opacifier Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229950002342 bisfentidine Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical class CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- FXJAOWANXXJWGJ-UHFFFAOYSA-N n-[4-(2-methyl-1h-imidazol-5-yl)phenyl]-n'-propan-2-ylmethanimidamide Chemical compound C1=CC(NC=NC(C)C)=CC=C1C1=CN=C(C)N1 FXJAOWANXXJWGJ-UHFFFAOYSA-N 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- KRCQSTCYZUOBHN-UHFFFAOYSA-N rabeprazole sodium Chemical compound [Na+].COCCCOC1=CC=NC(CS(=O)C=2[N-]C3=CC=CC=C3N=2)=C1C KRCQSTCYZUOBHN-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
释放度% | 1 | 2 | 3 | 4 | 5 | 6 |
实施例1 | 93.35 | 92.71 | 94.27 | 94.22 | 92.47 | 94.04 |
实施例2 | 94.28 | 93.95 | 89.74 | 93.25 | 93.81 | 93.14 |
实施例3 | 94.15 | 93.61 | 94.94 | 94.56 | 95.84 | 95.42 |
杂质% | 0月 | 12月 | 24月 |
实施例1 | 0.7 | 0.8 | 1.0 |
实施例2 | 0.8 | 1.0 | 1.2 |
实施例3 | 0.7 | 0.8 | 1.0 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010603181 CN102552159B (zh) | 2010-12-22 | 2010-12-22 | 雷贝拉唑钠肠溶微丸及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010603181 CN102552159B (zh) | 2010-12-22 | 2010-12-22 | 雷贝拉唑钠肠溶微丸及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102552159A true CN102552159A (zh) | 2012-07-11 |
CN102552159B CN102552159B (zh) | 2013-07-17 |
Family
ID=46399630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201010603181 Active CN102552159B (zh) | 2010-12-22 | 2010-12-22 | 雷贝拉唑钠肠溶微丸及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102552159B (zh) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103202819A (zh) * | 2012-11-19 | 2013-07-17 | 山东罗欣药业股份有限公司 | 一种雷贝拉唑钠肠溶片及其制备方法 |
CN103340829A (zh) * | 2013-07-26 | 2013-10-09 | 珠海润都制药股份有限公司 | 一种质子泵抑制剂肠溶微丸 |
CN103356489A (zh) * | 2013-08-05 | 2013-10-23 | 谢斌 | 一种质子泵抑制剂肠溶微丸及其制剂、制备方法 |
CN103599087A (zh) * | 2013-05-21 | 2014-02-26 | 海南海力制药有限公司 | 雷贝拉唑钠肠溶微丸及其制备方法 |
CN104606146A (zh) * | 2015-02-11 | 2015-05-13 | 苏州大学 | 一种埃索美拉唑镁肠溶微丸制剂及其制备方法 |
CN104997757A (zh) * | 2015-07-16 | 2015-10-28 | 广东彼迪药业有限公司 | 雷贝拉唑钠肠溶微丸胶囊及其制备方法 |
CN105106168A (zh) * | 2015-08-19 | 2015-12-02 | 德州德药制药有限公司 | 一种埃索美拉唑镁肠胶囊及其制备方法 |
CN105796532A (zh) * | 2016-03-28 | 2016-07-27 | 中国医药集团总公司四川抗菌素工业研究所 | 一种雷贝拉唑钠缓释胶囊及其制备方法 |
CN110946845A (zh) * | 2018-09-26 | 2020-04-03 | 河南天晟泰丰医药科技有限公司 | 一种右旋雷贝拉唑钠缓释胶囊及其制备方法 |
CN111481525A (zh) * | 2020-04-21 | 2020-08-04 | 广东一力罗定制药有限公司 | 奥美拉唑肠溶微丸及其生产工艺 |
WO2023137556A1 (en) * | 2022-01-20 | 2023-07-27 | Bionxt Solutions Inc. | Chemical composition for enteric drug delivery |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1546025A (zh) * | 2003-12-12 | 2004-11-17 | 南京长澳医药科技有限公司 | 泮托拉唑钠肠溶微丸 |
CN101036633A (zh) * | 2007-04-28 | 2007-09-19 | 杭州民生药业集团有限公司 | 一种奥美拉唑肠溶微丸胶囊及其制备方法 |
CN101507718A (zh) * | 2009-03-03 | 2009-08-19 | 张登科 | 雷贝拉唑钠肠溶口崩片及其制备方法 |
CN101507713A (zh) * | 2009-03-24 | 2009-08-19 | 涂家生 | 一种高生物利用度的质子泵抑制剂缓释技术 |
WO2010122583A2 (en) * | 2009-04-24 | 2010-10-28 | Rubicon Research Private Limited | Oral pharmaceutical compositions of acid labile substances |
-
2010
- 2010-12-22 CN CN 201010603181 patent/CN102552159B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1546025A (zh) * | 2003-12-12 | 2004-11-17 | 南京长澳医药科技有限公司 | 泮托拉唑钠肠溶微丸 |
CN101036633A (zh) * | 2007-04-28 | 2007-09-19 | 杭州民生药业集团有限公司 | 一种奥美拉唑肠溶微丸胶囊及其制备方法 |
CN101507718A (zh) * | 2009-03-03 | 2009-08-19 | 张登科 | 雷贝拉唑钠肠溶口崩片及其制备方法 |
CN101507713A (zh) * | 2009-03-24 | 2009-08-19 | 涂家生 | 一种高生物利用度的质子泵抑制剂缓释技术 |
WO2010122583A2 (en) * | 2009-04-24 | 2010-10-28 | Rubicon Research Private Limited | Oral pharmaceutical compositions of acid labile substances |
Non-Patent Citations (1)
Title |
---|
傅雪猛等: "雷贝拉唑钠肠溶(微粒)胶囊的制备工艺研究", 《中国药业》 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103202819A (zh) * | 2012-11-19 | 2013-07-17 | 山东罗欣药业股份有限公司 | 一种雷贝拉唑钠肠溶片及其制备方法 |
CN103599087A (zh) * | 2013-05-21 | 2014-02-26 | 海南海力制药有限公司 | 雷贝拉唑钠肠溶微丸及其制备方法 |
CN103340829A (zh) * | 2013-07-26 | 2013-10-09 | 珠海润都制药股份有限公司 | 一种质子泵抑制剂肠溶微丸 |
CN103356489A (zh) * | 2013-08-05 | 2013-10-23 | 谢斌 | 一种质子泵抑制剂肠溶微丸及其制剂、制备方法 |
CN103356489B (zh) * | 2013-08-05 | 2015-03-18 | 谢斌 | 一种质子泵抑制剂肠溶微丸及其制剂、制备方法 |
CN104606146B (zh) * | 2015-02-11 | 2017-12-19 | 苏州大学 | 一种埃索美拉唑镁肠溶微丸制剂及其制备方法 |
CN104606146A (zh) * | 2015-02-11 | 2015-05-13 | 苏州大学 | 一种埃索美拉唑镁肠溶微丸制剂及其制备方法 |
CN104997757A (zh) * | 2015-07-16 | 2015-10-28 | 广东彼迪药业有限公司 | 雷贝拉唑钠肠溶微丸胶囊及其制备方法 |
CN105106168A (zh) * | 2015-08-19 | 2015-12-02 | 德州德药制药有限公司 | 一种埃索美拉唑镁肠胶囊及其制备方法 |
CN105106168B (zh) * | 2015-08-19 | 2018-03-06 | 德州德药制药有限公司 | 一种埃索美拉唑镁肠胶囊及其制备方法 |
CN105796532A (zh) * | 2016-03-28 | 2016-07-27 | 中国医药集团总公司四川抗菌素工业研究所 | 一种雷贝拉唑钠缓释胶囊及其制备方法 |
CN110946845A (zh) * | 2018-09-26 | 2020-04-03 | 河南天晟泰丰医药科技有限公司 | 一种右旋雷贝拉唑钠缓释胶囊及其制备方法 |
CN111481525A (zh) * | 2020-04-21 | 2020-08-04 | 广东一力罗定制药有限公司 | 奥美拉唑肠溶微丸及其生产工艺 |
WO2023137556A1 (en) * | 2022-01-20 | 2023-07-27 | Bionxt Solutions Inc. | Chemical composition for enteric drug delivery |
Also Published As
Publication number | Publication date |
---|---|
CN102552159B (zh) | 2013-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102552159B (zh) | 雷贝拉唑钠肠溶微丸及其制备方法 | |
RU2095054C1 (ru) | Твердая лекарственная форма для орального введения | |
CN100490790C (zh) | 一种奥美拉唑肠溶微丸胶囊及其制备方法 | |
CN101596165B (zh) | 泮托拉唑钠肠溶微丸 | |
CN103006607B (zh) | 一种兰索拉唑肠溶片及其制备方法 | |
SA97170553B1 (ar) | اشكال معايرة جرعات صيدلانية تعطى بالفم تتضمن مثبط مضخة البروتون proton pump inhibitor وعامل مضاد للحموضة او الجينات alginate | |
CN103356489B (zh) | 一种质子泵抑制剂肠溶微丸及其制剂、制备方法 | |
WO2012074110A1 (ja) | 口腔内崩壊錠 | |
CN101816641A (zh) | 一种奥美拉唑速释固体制剂及其制备方法 | |
US8685448B2 (en) | Pharmaceutical solid dosage form | |
ES2667402T3 (es) | Composición farmacéutica de omeprazol | |
CN102085188B (zh) | 一种兰索拉唑肠溶微丸的制备方法 | |
CN103599087A (zh) | 雷贝拉唑钠肠溶微丸及其制备方法 | |
CN1321642C (zh) | 泮托拉唑钠肠溶微丸 | |
CN105434398A (zh) | 一种雷贝拉唑肠溶微丸及其制备方法 | |
CN105126108A (zh) | 一种含有阿司匹林和质子泵抑制剂的复方胶囊 | |
CN105816436B (zh) | 一种泮托拉唑肠溶微丸、泮托拉唑肠溶缓控释片剂及其制备方法 | |
CN104224728A (zh) | 一种埃索美拉唑肠溶微丸及其制备方法 | |
CN101780048A (zh) | 一种以泮托拉唑钠为主要成分的肠溶固体制剂及其制备方法 | |
CN104546899A (zh) | 一种含有奥美拉唑的口服固体药物组合物 | |
CN114191411B (zh) | 一种质子泵抑制剂胶囊及其制备方法 | |
CN107375226A (zh) | 雷贝拉唑钠肠溶片及其制备方法 | |
CN103006611A (zh) | 一种奥美拉唑肠溶双层缓释片剂 | |
CN104739801A (zh) | 一种治疗消化系统疾病的药物组合物 | |
CN104606168A (zh) | 一种治疗消化系统疾病的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: He Hongyan Inventor after: Xie Shaofei Inventor after: Wu Xiaotao Inventor after: Xu Li Inventor after: Zhong Xuebin Inventor after: Song Qiaoli Inventor after: Li Wei Inventor after: Huo Liru Inventor after: Sun Xiao Inventor after: Li Zhan Inventor before: He Hongyan Inventor before: Wu Xiaotao Inventor before: Xu Li Inventor before: Zhong Xuebin Inventor before: Song Qiaoli Inventor before: Li Wei Inventor before: Huo Liru Inventor before: Sun Xiao |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: HE HONGYAN WU XIAOTAO XU LI ZHONG XUEBIN SONG QIAOLI LI WEI HUO LIRU SUN XIAO TO: HE HONGYAN WU XIAOTAO XU LI ZHONG XUEBIN SONG QIAOLI LI WEI HUO LIRU SUN XIAO LI ZHAN XIE SHAOFEI |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP02 | Change in the address of a patent holder |
Address after: No. 63 Kexin Road, Jiangbei New District, Nanjing City, Jiangsu Province, 210000 Co-patentee after: C & O Pharmaceutical Technology (Holdings) Ltd. Patentee after: Chang'ao Science and Technology of Medical Industry Co., Ltd., Nanjing Address before: 210038 Nanjing economic and Technological Development Zone, Jiangsu Province, No. Wing Road, No. 1 Co-patentee before: C & O Pharmaceutical Technology (Holdings) Ltd. Patentee before: Chang'ao Science and Technology of Medical Industry Co., Ltd., Nanjing |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: 210038 Nanjing economic and Technological Development Zone, Jiangsu Province, No. Wing Road, No. 1 Patentee after: Nanjing Changao Pharmaceutical Science & Technology Co.,Ltd. Patentee after: CHANG'AO PHARMACEUTICAL TECHNOLOGY (HOLDINGS) Ltd. Address before: No. 63 Kexin Road, Jiangbei New District, Nanjing City, Jiangsu Province, 210000 Patentee before: Nanjing Changao Pharmaceutical Science & Technology Co.,Ltd. Patentee before: CHANG'AO PHARMACEUTICAL TECHNOLOGY (HOLDINGS) Ltd. |
|
CP02 | Change in the address of a patent holder |